Literature DB >> 3440868

An unusual metabolic myopathy: a malate-aspartate shuttle defect.

D J Hayes1, D J Taylor, P J Bore, D Hilton-Jones, D L Arnold, M V Squier, A E Gent, G K Radda.   

Abstract

Studies on a 27-year-old man with a 3-year history of exercise-induced muscle pain, passage of red urine and elevated serum creatine kinase are described. Histological examination of a biopsy from quadriceps revealed non-specific myopathic changes with occasional clusters of subsarcolemmal mitochondria. The phosphorylase stain was normal. Phosphorous nuclear magnetic resonance (NMR) spectroscopy studies of gastrocnemius and flexor digitorum superficialis muscles showed no abnormalities at rest. During aerobic exercise there was an abnormally rapid decrease in phosphocreatine concentration but the pH remained within the normal range. There was a build-up of phosphomonoester (probably glucose 6-phosphate), usually indicative of a block in glycolysis. However, a primary defect in the glycolytic pathway seemed unlikely because muscle acidified normally during ischaemic exercise. Recovery from exercise was unusual in that phosphocreatine resynthesis and inorganic phosphate disappearance followed similar prolonged time courses (in control subjects the rate of inorganic phosphate disappearance was about twice as fast as the rate of phosphocreatine resynthesis). The transport of inorganic phosphate into the mitochondria appeared to be delayed. These slow recovery data suggested that oxidative metabolism was impaired. However, with all substrates tested, isolated muscle mitochondria had rates of oxygen uptake that were similar to control values, thereby ruling out a primary defect in mitochondrial respiration. A system involving several mitochondrial transport systems, the malate-aspartate shuttle, was measured. The activity in the patient's isolated mitochondria was less than 20% of the activity present in samples from control subjects. This patient is the only one so far reported with a defect involving the malate-aspartate shuttle system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3440868     DOI: 10.1016/0022-510x(87)90004-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

Review 1.  Mitochondrial membrane transporters and metabolic switch in heart failure.

Authors:  Vikas Kumar; T R Santhosh Kumar; C C Kartha
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 2.  Defects in the mitochondrial energy metabolism outside the respiratory chain and the pyruvate dehydrogenase complex.

Authors:  F J Trijbels; W Ruitenbeek; M Huizing; U Wendel; J A Smeitink; R C Sengers
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

3.  Central activation of autonomic effectors during mental simulation of motor actions in man.

Authors:  J Decety; M Jeannerod; D Durozard; G Baverel
Journal:  J Physiol       Date:  1993-02       Impact factor: 5.182

4.  Role of NADH/NAD+ transport activity and glycogen store on skeletal muscle energy metabolism during exercise: in silico studies.

Authors:  Yanjun Li; Ranjan K Dash; Jaeyeon Kim; Gerald M Saidel; Marco E Cabrera
Journal:  Am J Physiol Cell Physiol       Date:  2008-10-01       Impact factor: 4.249

5.  Human mitochondrial transmembrane metabolite carriers: tissue distribution and its implication for mitochondrial disorders.

Authors:  M Huizing; W Ruitenbeek; L P van den Heuvel; V Dolce; V Iacobazzi; J A Smeitink; F Palmieri; J M Trijbels
Journal:  J Bioenerg Biomembr       Date:  1998-06       Impact factor: 2.945

Review 6.  Importance of mitochondrial transmembrane processes in human mitochondriopathies.

Authors:  M Huizing; V DePinto; W Ruitenbeek; F J Trijbels; L P van den Heuvel; U Wendel
Journal:  J Bioenerg Biomembr       Date:  1996-04       Impact factor: 2.945

Review 7.  The malate-aspartate shuttle (Borst cycle): How it started and developed into a major metabolic pathway.

Authors:  Piet Borst
Journal:  IUBMB Life       Date:  2020-09-11       Impact factor: 3.885

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.